CellBion

Advancing Global Healthcare with Innovative Radiopharmaceuticals

General Information
Company Name
CellBion
Founded Year
2010
Location (Offices)
Korea South +1
Founders / Decision Makers
Number of Employees
6
Industries
Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage
Series Unknown
Social Media

CellBion - Company Profile

CellBion is a biotechnology and pharmaceutical startup founded in 2010 with the slogan "Advancing Global Healthcare with Innovative Radiopharmaceuticals". The company is based in South Korea and has recently received a significant KRW8.00B Venture Round investment on 26 October 2023 from prominent investors including Hana Ventures, Huons, and SINSIN-PHARM. CellBion is dedicated to revolutionizing healthcare through precision medicine, leveraging advanced technology and a highly experienced team to develop safe and effective solutions for medical imaging and therapeutic use. With a strong commitment to improving patient outcomes, the company aims to make a positive impact on global healthcare.

Taxonomy: radiopharmaceuticals, precision medicine, medical imaging, therapeutic solutions, patient outcomes, technology, global impact

Funding Rounds & Investors of CellBion (3)

View All
Funding Stage Amount No. Investors Investors Date
Venture Round KRW8.00B 3 SINSIN-PHARM 26 Oct 2023
Venture Round Unknown 1 01 Jan 2019
Venture Round Unknown 1 01 Jan 2012

Latest News of CellBion

View All

No recent news or press coverage available for CellBion.

Similar Companies to CellBion

View All
Sara Pharmaceuticals - Similar company to CellBion
Sara Pharmaceuticals Sara Pharmaceuticals are the pioneers in the manufacture of Parenteral Products - Small Volume Parenterals
Apex Commercial Group, LLC - Similar company to CellBion
Apex Commercial Group, LLC Locally Owned. Strategically Connected. Client Focused.
937 Payroll - Similar company to CellBion
937 Payroll Local. Dedicated. Easy. Payroll Solutions.
Clique - Similar company to CellBion
Clique A digital-first approach to business strategy.